The extensive body of research from Mayo Clinic emphasizes major advancements in obesity, including prediction of GLP-1 side effects, a new obesity sub-phenotype, and insights into personalized bariatric and endoscopic procedures.

MENLO PARK, Calif., April 23, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced the presentation of 17 groundbreaking studies at Digestive Disease Week (DDW) 2025, taking place May 4-6 in San Diego. Presented by Mayo Clinic researchers, these studies, eight of which include the use of Phenomix's predictive machine learning algorithms, represent major strides in understanding and treating obesity as a complex, biologically driven disease. The findings include significant advances in predicting response to GLP-1 therapies, identification of a new obesity sub-phenotype, and new data guiding bariatric and endobariatric treatment decisions. Collectively, the research highlights the growing role of precision medicine in obesity care to guide treatment decisions, as well as drug and device development.

The research, led by renowned obesity researcher and Phenomix co-founder, Andres Acosta, MD, PhD, alongside his multidisciplinary team at Mayo Clinic, highlights three key breakthroughs being shared publicly for the first time, including:

• Predicting Side Effects to GLP-1 Therapies - This study reveals new genetic risk scores (GRS) that can predict which patients are more likely to experience side effects, such as nausea, in response to GLP-1 therapies. These insights, powered by the MyPhenome® test, may enable better medication matching and improve both patient outcomes and trial design for anti-obesity medications (AOMs). Featured session:
  • A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis of a Randomized Controlled Trial of Liraglutide | Sunday, May 4, 12:30-1:30 pm PST, Main Session (0012)
    
    
• Discovery of a New Obesity Sub-Phenotype - In a prestigious plenary session, researchers will unveil a newly identified sub-phenotype of obesity, in which rapid gastric emptying (Hungry Gut) is paired with reduced GLP-1 synthesis and secretion, two traits typically not seen together. This finding challenges current assumptions about hunger signaling and could explain why some patients struggle with persistent hunger and poor treatment response. The study lays the groundwork for more targeted therapies, from AOMs to surgical options, mirroring the evolution of treatment seen in oncology. Featured session:
  • Deep Phenotyping of Obesity Reveals a Sub-phenotype with Physiologically Discordant Rapid Gastric Emptying and Reduced GLP-1 Synthesis and Secretion | Monday, May 5, 4:30-4:50 p.m. PST, Main Session (0004)
    
    
• Predicting Response, Risk to Bariatric and Endoscopic Treatment - New research shows how MyPhenome can help identify which patients are most likely to benefit from bariatric and endoscopic procedures, as well as who is at greater risk for chronic conditions like metabolic dysfunction-associated steatotic liver disease (MASLD). For the first time, these findings provide evidence for integrating the MyPhenome test into bariatric and endobariatric procedure planning as well as disease prevention strategies. Featured sessions:
  • A Genetic Risk Score for Postprandial Satiety is Associated with Improved Weight Loss After Endoscopic Bariatric Therapies: A Multicenter Cohort Analysis | Sunday, May 4, 12:30-1:30 p.m. PST, Main Session (0001)
  • A machine-learning assisted gene risk score for calories to satiation predicts weight loss outcomes after Roux-en-Y gastric bypass surgery | Tuesday, May 6, 2:30-2:45 pm PST, Main Session (0003)

"These findings mark a major step toward truly personalized obesity care, not just in drug response but also in bariatric procedures, device selection, and future drug development," Dr. Acosta said. "For years, our team has worked to demonstrate that obesity is a biologically complex and highly individual disease. Our valued partnership with Phenomix Sciences has been instrumental in advancing this work and has paved the way for more effective, patient-specific treatments."

"We are thrilled to see the depth of obesity research being presented at this year's conference, reflecting the rapid advancements in obesity precision medicine," said Mark Bagnall, CEO of Phenomix Sciences. "Collaborating with some of the world's top researchers is central to our mission. These breakthroughs demonstrate the value of the close relationship with Mayo Clinic, the strength of our underlying technology in developing disease-relevant predictors and the utility of our marketed MyPhenome test. We look forward to leading a new era of obesity treatment that is smarter, more personalized, and more effective."

"These new findings further validate that obesity is a biologically complex and highly individual condition. Phenomix's work—especially in personalizing treatment approaches through physician-informed insights—is exactly the kind of transformative innovation we look to support at Health2047," said Larry Cohen, CEO of Health2047, a Phenomix investor and venture studio founded by the American Medical Association.

To learn more about Phenomix Sciences' extensive body of research, visit phenomixsciences.com. To see a full list of studies being presented at DDW, click here.

About Phenomix Sciences
Phenomix Sciences is a precision obesity biotechnology company transforming obesity medicine by delivering individualized insights into how patients respond to specific weight loss interventions. These insights not only inform clinical decision-making for patients, but also help pharmaceutical and medical device partners refine trials, identify high-responder populations, and accelerate the development of more targeted, effective therapies. Launched in 2024, the company's MyPhenome® test was named one of TIME's Best Inventions of 2024. By using AI and machine learning technologies to align patient biology with obesity medicine, Phenomix is shaping a more personalized and impactful future for obesity treatment. Phenomix's technology is exclusively licensed from Mayo Clinic and the company is backed by strategic investors including Health2047, a venture studio founded by the American Medical Association, DexCom, Inc. and Labcorp. Learn more at www.phenomixsciences.com.

Media Contact:
phenomix@ampublicrelations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/phenomix-sciences-and-mayo-clinic-to-present-landmark-research-at-ddw-2025-advancing-precision-obesity-medicine-302435830.html

SOURCE Phenomix Sciences